NEIL KAHN: Open Payments
NPI 1831190602 · DECATUR, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,278 in 111 payments from 15 companies in 2025. Trend: 2023 $1,722 · 2024 $2,025 · 2025 $2,278
Food & beverage: $2,198Education: $80
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 23 | $347 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $331 |
| E.R. Squibb & Sons, L.L.C. | 10 | $298 |
| Neurocrine BioSciences, Inc. | 11 | $241 |
| Alkermes, Inc. | 12 | $239 |
| Teva Pharmaceuticals USA, Inc. | 5 | $168 |
| Janssen Pharmaceuticals, Inc | 7 | $158 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $143 |
| Lundbeck LLC | 6 | $125 |
| Axsome Therapeutics, Inc. | 3 | $72 |
Products named: REXULTI, CAPLYTA, COBENFY, INGREZZA, ARISTADA, TRINTELLIX, SPRAVATO, Auvelity.
Industry payments across GA — which companies pay providers there.
